Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD)

References

• Smith R. The triumph of NICE. BMJ 2004;329:0
   Google Scholar
• Schlander M. NICE accountability for reasonableness. A qualitative case study of its appraisal of treatments for attentiondeficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007;23:313–21
   Google Scholar
• National Institute for Health and Clinical Excellence [NICE]. Technology Appraisal 98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13. London: NICE, March 2006
   Google Scholar
• Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104–13
   PubMedGoogle Scholar
• Wilens TE, Dodson W. A clinical perspective of attentiondeficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004;65:1301–13
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attentiondeficit/hyperactivity disorder among adolescents: a review of diagnosis, treatment, and clinical implications. Pediatrics 2005;115:1734–46
   PubMed Web of Science ®Google Scholar
• Leibson CL, Long KH. Economic implications of attentiondeficit/hyperactivity disorder for healthcare systems. Pharmacoeconomics 2003;21:1239–62
   PubMed Web of Science ®Google Scholar
• Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003;42:1415–23
   PubMed Web of Science ®Google Scholar
• Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005;3:5
   PubMedGoogle Scholar
• Mannuzza S, Klein RG, Moulton JL 3rd. Persistence of attention-deficit/hyperactivity disorder into adulthood: what have we learnt from the prospective follow-up studies? J Atten Disord 2003;7: 93–100
   Google Scholar
• Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:233–60
   PubMed Web of Science ®Google Scholar
• Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 2004;35:346.e1–9
   PubMedGoogle Scholar
• Lam LT. Attention deficit disorder and hospitalization due to injury among older adolescents in New South Wales, Australia. J Atten Disord 2002;6:77–82
   PubMedGoogle Scholar
• Hoare P, Beattie T. Children with attention deficit hyperactivity disorder and attendance at hospital. Eur J Emerg Med 2003;10:98–100
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J. Alcohol, drugs, and attention-deficit/hyperactivity disorder: a model for the study of addictions in youth. J Psychopharmacol 2006;20:580–8
   PubMed Web of Science ®Google Scholar
• Thapar A, van den Bree M, Fowler T, et al. Predictors of antisocial behaviour in children with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry 2006;15:118–25
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000;39:1424–31
   PubMed Web of Science ®Google Scholar
• Rösler M, Retz W, Retz-Junginger P, et al. Prevalence of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004;254:365–71
   Google Scholar
• Siponmaa L, Kristiansson M, Jonson C, et al. Juvenile and young adult mentally disordered offenders: the role of child neuropsychiatric disorders. J Am Acad Psychiatry Law 2001;29:420–6
   PubMed Web of Science ®Google Scholar
• Johansson P, Kerr M, Andershed H. Linking adult psychopathy with childhood hyperactivity-impulsivity-attention problems and conduct problems through retrospective self-reports. J Personal Disord 2005;19:94–101
   Google Scholar
• Sourander A, Elonheimo H, Niemela S, et al. Childhood predictors of male criminality: a prospective population-based follow-up study from age 8 to late adolescence. J Am Acad Child Adolesc Psychiatry 2006;45:578–86
   PubMed Web of Science ®Google Scholar
• Mannuza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997;36:1222–7
   PubMed Web of Science ®Google Scholar
• Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med 2005;352:165–73
   PubMed Web of Science ®Google Scholar
• Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann NY Acad Sci 2001;931:310341
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence [NICE]. Health Technology Appraisal: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents including review of existing guidance number 13 (Guidance on the Use of Methylphenidate [Ritalin, Equasym] for Attention Deficit/Hyperactivity Disorder [ADHD] in childhood) – Scope. London: NICE, August 2003
   Google Scholar
• National Institute for Health and Clinical Excellence [NICE]. Final Appraisal Determination: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. London: NICE, May 2005
   Google Scholar
• King S, Griffin S, Hodges Z, et al. A systematic review of the clinical and cost-effectiveness of methylphenidate hydrochloride, dexamfetamine sulphate and atomoxetine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (commercial in confidence information removed). York: December 2004
   Google Scholar
• Scottish Medicines Consortium. Atomoxetine capsules 10mg to 60mg (Strattera). No. 153/05. February 04, 2005, published online March 07, 2005 , at: http://www.scottishmedicines.org.uk/medicines/default.asp. Last access February 15, 2006
   Google Scholar
• Scottish Medicines Consortium. Atomoxetine capsules 10mg to 60mg (Strattera). No. 153/05. June 10, 2005, published online July 11, 2005 , at: http://www.scottishmedicines.org.uk/medicines/default.asp. Last access February 15, 2006
   Google Scholar
• Australian Government, Department of Health and Ageing. November 2005 PBAC Outcomes – Subsequent decisions not to recommend. Available online at: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbacrec-pbacrecnov05subsequent_rejections. November 2005. Last accessed February 15, 2006
   Google Scholar
• Australian Government, Department of Health and Ageing. Atomoxetine hydrochloride, capsules, 10mg, 18mg, 25mg, 40mg and 60mg, StratteraR, November 2005. Available online at: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-psd-atomoxetine-nov05. November 2005. Last accessed September 01, 2006
   Google Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;May 5 (epub ahead of print)
   Google Scholar
• Blades CA, Culyer AJ, Walker AM. Health service efficiency: appraising the appraisers: a critical review of economic appraisal in practice. Social Sci Med 1987;25:461–72
   Google Scholar
• Schlander M. Commentary: Has NICE got it right? Curr Med Res Opin, 23: in press
   Google Scholar
• National Institute for Clinical Excellence (NICE). Guide to the Technology Appraisal Process (reference N0514). London: NICE, April 2004
   Google Scholar
• National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal (reference N0515). London: NICE, April 2004
   Google Scholar
• Byford S, Palmer S. Common errors and controversies in pharmacoeconomic analyses. Pharmacoeconomics 1998;13:659–66
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med 2000;132:964–72
   PubMed Web of Science ®Google Scholar
• Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA 2002;287:2809–12
   Google Scholar
• Schlander M. Health Technology Assessments by the National Institute for Health and Clinical Excellence: A Qualitative Study. New York, NY: Springer, 2007
   Google Scholar
• Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff 1998;17:50–64
   PubMed Web of Science ®Google Scholar
• Daniels N, Sabin JE. Setting Limits Fairly – Can We Learn to Share Medical Resources? Oxford: Oxford University Press, 2002
   Google Scholar
• King S, Riemsma R, Hodges Z, et al. Technology Assessment Report for the HTA Programme: Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder. Final version. London: NICE, June 2004. (Published online October 12, 2004: http://wwwnice.org.uk/page.aspx?o=adhd)
   Google Scholar
• Dundar Y, Dodd S, Dickson R, et al. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technol Assess 2006;10
   Web of Science ®Google Scholar
• King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006;10
   Web of Science ®Google Scholar
• Newcorn JH, Owens JA, Jasinski DR, et al. Results from recently completed comparator studies with atomoxetine and methylphenidate. 51st Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP), Washington, DC: Symposium 20, October 21, 2004
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE): Appraisal of methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder in children and adolescents: Appeal Panel Decision. London: NICE, December 8, 2005 . Source: www.nice.org.uk/page.aspx?o=283566. Accessed December 20, 2005
   Google Scholar
• National Institute for Health and Clinical Excellence [NICE]. Draft Scope: Attention deficit hyperactivity disorder: identification and management of ADHD in children, young people and adults. London: NICE, January 31, 2006 . Source: www.nice.org.uk/page.aspx?o=290880. Accessed February 12, 2006
   Google Scholar
• National Institute for Health and Clinical Excellence [NICE]. Final Scope: Attention deficit hyperactivity disorder: identification and management of ADHD in children, young people and adults. London: NICE, August 8, 2006 . Source: www.nice.org.uk/page.aspx?o=351276. Accessed September 30, 2006
   Google Scholar
• Taylor E, Sergeant J, Doepfner M, et al. Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry 1998;7:184–200
   PubMed Web of Science ®Google Scholar
• Tripp G, Luk SL, Schaughency, EA, Singh R. DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorder. J Am Acad Child Adolesc Psychiatry 1999;38: 156–64
   Google Scholar
• Wolraich ML, Hannah JN, Baumgaertel A, Feurer ID. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Dev Behav Pediatr 1998;19:162–8
   PubMed Web of Science ®Google Scholar
• Taylor E, Doepfner M, Sergeant J, et al. European guidelines for hyperkinetic disorder – first upgrade. Eur Child Adoles Psychiatry 2004;13 (Suppl 1):7–30
   PubMed Web of Science ®Google Scholar
• Taylor E. Hyperkinetic disorders. In Gillberg C, Harrington R, Steinhausen H-C, eds. A Clinician’s Handbook of Child and Adolescent Psychiatry. Cambridge: Cambridge University Press, 2006:489–521
   Google Scholar
• Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V. Scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003;42:1015–37
   Google Scholar
• American Psychiatric Association [APA]. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• Schachar R, Jadad AR, Gauld M, et al. Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Can J Psychiatry 2002;47:337–48
   PubMed Web of Science ®Google Scholar
• Jadad AR, Boyle M, Cunningham C, et al. Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report / Technology Assessment No 11 (prepared by McMaster University under contract no 290–97–0017). AHRQ Publication No 00-E005. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), November 1999
   Google Scholar
• Danckaerts M, Heptinstall E, Chadwick O, Taylor E. Self-report of attention deficit hyperactivity disorder in adolescents. Psychopathology 1999;32:81–92
   PubMed Web of Science ®Google Scholar
• Conners CK. Conners’ Rating Scales – Revised (CRS-R). In: American Psychiatric Association, Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000:329–32
   Google Scholar
• Miller A, Lee SK, Raina P, et al. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998
   Google Scholar
• Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999;44:1007–16
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073–86
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1088–96
   PubMed Web of Science ®Google Scholar
• Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5:833–41
   PubMedGoogle Scholar
• Newcorn J, Kratochvil CJ, Allen AJ, et al. Atomoxetine and OROS methylphenidate for the treatment of ADHD: acute results and methodological issues. Poster presentation at 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health (NIMH), Boca Raton, FL, June 6–9, 2005, Book of Abstracts, p. 188
   Google Scholar
• Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose response study. Pediatrics 2001;1008: e83/1–9
   Google Scholar
• Hunter JE, Schmidt FL. Dichotomization of continuous variables: the implications for meta-analysis. J Appl Psychol 1990;75:334–49
   Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No ADM 76–338). Rockville, MD: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, 1976:218–22
   Google Scholar
• Beneke M, Rasmus W. ‘Clinical Global Impressions’ (ECDEU): some critical comments. Pharmacopsychiatry 1992;25:171–6
   PubMed Web of Science ®Google Scholar
• Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 1992;28:425–32
   Google Scholar
• Guy W. Clinical Global Impressions (CGI) Scale. In: American Psychiatric Association, Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000:100–2
   Google Scholar
• Coghill D, Spencer Q, Barton J, et al. Measuring quality of life in children with attention-deficit/hyperactivity disorder in the UK. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Book of Abstracts. Darmstadt: Steinkopff-Verlag, 2004:327
   Google Scholar
• Secnik K, Cottrell S, Matza LS, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. Value Health 2004;7:236
   Web of Science ®Google Scholar
• Sharp WS, Alter JM, Marsh WL, et al. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 1999;38:40–7
   PubMed Web of Science ®Google Scholar
• Arnold LE. Sex differences in ADHD: conference summary. J Abnorm Child Psychol 1996;24:555–69
   PubMed Web of Science ®Google Scholar
• Biederman J, Kwon A, Aleardi M, et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry 2005;162:1083–9
   PubMed Web of Science ®Google Scholar
• Kemner JE, Starr HL, Brown DL, et al. Greater improvement and response rates with OROS MPH vs atomoxetine in children with ADHD. Presentation at the XXIVth Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Paris, France, June 20–24, 2004
   Google Scholar
• Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Advan Ther 2005;22:498–512
   PubMed Web of Science ®Google Scholar
• Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967;20:637–48
   PubMedGoogle Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices – modeling studies. Value Health 2003;6:9–17
   PubMed Web of Science ®Google Scholar
• Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford University Press,1997
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005
   Google Scholar
• March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836–46
   PubMed Web of Science ®Google Scholar
• Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health 2005;8:521–33
   PubMed Web of Science ®Google Scholar
• Hughes DA, Bagust A, Haycox A, Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001;19:1185–97
   PubMed Web of Science ®Google Scholar
• Biederman J, Arnsten AFT, Faraone SV, et al. New developments in the treatment of ADHD. J Clin Psychiatry 2006;67:148–59
   PubMed Web of Science ®Google Scholar
• Weiss M, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006;67 (suppl 8):38–45
   Google Scholar
• Meredith PA. Achieving and assessing therapeutic coverage. In Métry J-M, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester: John Wiley, 1999:41–60
   Google Scholar
• Swanson J. Compliance with stimulants for attention-deficit / hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 2003;17:117–31
   Google Scholar
• Wilens T. Subtypes of ADHD at risk for substance abuse. Presentation at the 157th Annual Meeting of the American Psychiatric Association; New York, NY: May 1–6, 2004
   Google Scholar
• Graff Low K, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med 2002;7:283–7
   Google Scholar
• Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310
   Google Scholar
• Métry J-M. Measuring compliance in clinical trials and ambulatory care. In: Métry J-M, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester: John Wiley, 1999:1–21
   Google Scholar
• Peck C. Non-compliance and clinical trials: regulatory perspectives. In: Métry J-M, Meyer UA, eds. Drug Regimen Compliance. Issues in Clinical Trials and Patient Management. Chichester: John Wiley, 1999
   Google Scholar
• Swanson JM, Kinsbourne M, Roberts W, Zucker K. A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978:61:21–9
   PubMed Web of Science ®Google Scholar
• Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 1992;15: 1–27
   PubMed Web of Science ®Google Scholar
• Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999;37:457–70
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Perel JM, Rudolf G, et al. Correlations between motor persistence and plasma levels of methylphenidatetreated boys with ADHD. Int J Neuropsychopharmacology 2001;4:207–15
   PubMed Web of Science ®Google Scholar
• Pelham WE, Burrows-MacLean L, Gnagy EM, et al. Once-aday Concerta methylphenidate versus t.i.d. methylphenidate in natural settings. Pediatrics 2000;121:126–37
   Google Scholar
• Weinstein AG. Clinical management strategies to maintain compliance in asthmatic children. Ann Allergy Asthma Immunol 1995;74:304–10
   PubMed Web of Science ®Google Scholar
• American Academy of Child & Adolescent Psychiatry (AACAP). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41 (2 Suppl):26–49S
   Google Scholar
• Coghill D. Current issues in child and adolescent psychopharmacology. Part 1: Attention-deficit hyperactivity and affective disorders. Advan Psychiatr Treat 2003;9: 86–94
   Google Scholar
• Steinhoff K. Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action. Am J Manage Care 2004;10: S99–106
   PubMed Web of Science ®Google Scholar
• Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001;11:59–67
   PubMed Web of Science ®Google Scholar
• Métry J-M. Measuring compliance in clinical trials and ambulatory care. In Métry J-M, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester: John Wiley, 1999:1–21
   Google Scholar
• Miller AR, Lalonde CE, McGrail KM. Children’s persistence with methylphenidate therapy: a population-based study. Can J Psychiatry 2004;49:761–8
   Google Scholar
• Hwang P, Cosby A. Laberge ME. Compliance with three-times daily methylphenidate in children with attention-deficit/hyperactivity disorder. Value Health 2003;6:273
   Google Scholar
• Lage M, Hwang P. Methylphenidate formulation is associated with accident/injury rate in children with ADHD. Value Health 2003;6:688
   Web of Science ®Google Scholar
• Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 2004;14:575–81
   PubMed Web of Science ®Google Scholar
• Kemner JE, Lage MJ. Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm 2006;63:317–22
   PubMed Web of Science ®Google Scholar
• Kemner JE, Lage MJ. Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry 2006;5:1–8
   PubMedGoogle Scholar
• Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005;25:909–17
   PubMed Web of Science ®Google Scholar
• Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005;159:572–8
   PubMed Web of Science ®Google Scholar
• Freemantle N, Blonde L, Bolinder B, et al. Real-world trials to answer real-world questions. Pharmacoeconomics 2005;23:747–54
   PubMed Web of Science ®Google Scholar
• Drummond MF, Knapp MRJ, Burns TP, et al. Issues in the design of studies for the economic evaluation of new atypical antipsychotics: the ESTO study. J Ment Health Policy Econ 1998;1:15–22
   PubMedGoogle Scholar
• Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation: bridging the gap between clinical research and policy-making. Pharmacoeconomics 1996;16:449–58
   Google Scholar
• Revicki DA, Frank L. Pharmacoeconomic evaluations in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423–34
   PubMed Web of Science ®Google Scholar
• Steele M, Riccardelli R, Binder C. Effectiveness of OROSmethylphenidate vs. usual care with immediate release methylphenidate in ADHD children. Presentation at the American Psychiatric Association (APA) annual meeting, New York, NY, May 1–6th, 2004
   Google Scholar
• Steele M, Weiss M, Swanson J, et al. A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release-methylphenidate in attentiondeficit-hyperactivity-disorder. Can J Clin Pharmacol 2006;13: e50–62
   PubMedGoogle Scholar
• Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168–79
   PubMed Web of Science ®Google Scholar
• Lord J, Paisley S. The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood. London: National Institute for Clinical Excellence (NICE), Version 2, August 2000
   Google Scholar
• Zupancic JAF, Miller A, Raina P, et al. Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Rain P, et al. (eds.) A Review of Therapies for Attention-Deficit/ Hyperactivity Disorder. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998
   Google Scholar
• Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of attention-deficit/hyperactivity disorder (ADHD) treatments: estimates based upon the MTA Study. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Berlin, Germany, 2004. Book of Abstracts. Darmstadt: Steinkopff-Verlag 219
   Google Scholar
• Schlander M, Jensen PS, Foster EM, et al. Kosteneffektivität alternativer Behandlungsstrategien der Aufmerksamkeitsdefizit/Hyperaktivitätsstörung (ADHS): Erste Daten aus der amerikanischen MTA-Studie. Monatsschr Kinderheilkd 2004;152: Suppl. 1
   Google Scholar
• Annemans L, Ingham M. Estimating cost-effectiveness of Concerta OROS in attention-deficit/hyperactivity disorder (ADHD) – adapting the Canadian Coordinating Office for Health Technology Assessment’s (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent’s perspective. Value Health 2002;5:517
   Web of Science ®Google Scholar
• Schlander M. Cost-effectiveness of methylphenidate OROS for attention-deficit/hyperactivity disorder (ADHD): an evaluation from the perspective of the UK National Health Service (NHS). Value Health 2004;7:236
   Web of Science ®Google Scholar
• De Ridder A, De Graeve D. Estimating willingness to pay for drugs to treat ADHD – a contingent valuation study in students. Value Health 2002;5:462
   Web of Science ®Google Scholar
• Iskedjian M, Maturi B, Walker J, et al. Cost-effectiveness of atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents. Value Health 2003;3:275
   Google Scholar
• De Civita M, Regier D, Alamgir AH, et al. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics 2005;23:659–85
   PubMed Web of Science ®Google Scholar
• Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005;115: e600–14
   Google Scholar
• Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005;116: e364–9
   PubMed Web of Science ®Google Scholar
• Klassen A, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attentiondeficit/hyperactivity disorder. Pediatrics 2004;114:541–7
   Google Scholar
• Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002;41:530–7
   PubMed Web of Science ®Google Scholar
• Fischer M, Barkley RA, Fletcher KE, Smallish L. The stability of dimensions of behaviour in ADHD and normal children over an 8-year follow-up. J Abnorm Child Psychol 1993;21:315–37
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria. III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 1991;32:233–55
   PubMed Web of Science ®Google Scholar
• Loeber R, Green SM, Lahey BB, Stouthamer-Loeber M. Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior. J Abnorm Child Psychol 1991;19:75–95
   Google Scholar
• Wells KC. Comprehensive versus matched psychosocial treatment in the MTA Study: conceptual and empirical issues. J Clin Child Psychol 2001;30:131–5
   PubMed Web of Science ®Google Scholar
• Wells KC, Pelham WE, Kotkin RA, et al. Psychosocial treatment strategies in the MTA Study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 2000;28:483–505
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Abikoff H, Arnold LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1999;34:1304–13
   Google Scholar
• Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001;40:180–7
   PubMed Web of Science ®Google Scholar
• Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 2001;40:188–96
   PubMed Web of Science ®Google Scholar
• Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003;71:540–52
   PubMed Web of Science ®Google Scholar
• Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA Study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147–58
   PubMed Web of Science ®Google Scholar
• Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 2005;162:1628–36
   PubMed Web of Science ®Google Scholar
• Schlander M, Jensen PS, Foster EM, et al. Incremental costeffectiveness ratios of clinically proven treatments for attentiondeficit/hyperactivity disorder (ADHD): impact of diagnosticcriteria and comorbidity. 5th World Congress, InternationalHealth Economics Association (iHEA). Book of Abstracts. Barcelona, 2005:194–5
   Google Scholar
• Foster M, Jensen PS, Schlander M, et al. Treatment for ADHD: Is More Complex Treatment Cost-Effective for More Complex Cases? Health Services Research 2007; 42: 165–182
   PubMed Web of Science ®Google Scholar
• Steinhoff K, Wigal T, Swanson J. Single daily dose ADHD medication effect size evaluation. Poster presentation, 50th Annual Meeting of the American Academy for Child and Adolescent Psychiatry, Miami, FL, October 22–27, 2003
   Google Scholar
• Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel group study of SLI381 (Adderall XR) in children with attentiondeficit/hyperactivity disorder. Pediatrics 2002;110:258–66
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Greenhill LL, Pelham WL, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:883–92
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896–901
   PubMed Web of Science ®Google Scholar
• Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape 2003;8:1–7
   Google Scholar
• Abikoff HG, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:802–11
   PubMed Web of Science ®Google Scholar
• Klein RG, Abikoff HG, Hechtman L, Weiss G. Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2004;43:792–801
   PubMed Web of Science ®Google Scholar
• Kauffman RE, Smith-Right D, Reese CA, et al. Medication compliance in hyperactive children. Pediatr Pharmacol 1981;1:231–7
   PubMedGoogle Scholar
• Firestone P. Factors associated with children’s adherence to stimulant medication. Am J Orthopsychiatry 1982;252:447–57
   Google Scholar
• Sleator EK, Ullmann RK, von Neumann A. How do hyperactive children feel about taking stimulants and will they tell the doctor? Clin Pediatr 1982;21:474–9
   Google Scholar
• Brown RT, Borden KA, Clingerman SR. Adherence to methylphenidate therapy in a population: a preliminary investigation. Psychopharmacol Bull 1985;21:28–36
   Google Scholar
• Brown RT, Borden KA, Wynne ME, et al. Compliance with pharmacologic and cognitive treatment for attention deficit disorder. J Child Adolesc Psychopharmacol 1987;26:521–6
   Web of Science ®Google Scholar
• Johnston C, Fine S. Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol 1993;18:717–30
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109: e39/1–7
   Google Scholar
• Pliszka SR, Browne RG, Olvera RL, Wynne SK. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000;39:619–26
   PubMed Web of Science ®Google Scholar
• Faraone SV, Pliszka SR, Olvera RL, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. J Child Adolesc Psychopharmacol 2001;11:171–80
   PubMed Web of Science ®Google Scholar
• Klein RG, Abikoff H. Behavior therapy and methylphenidate in the treatment of children with ADHD. J Atten Disord 1997;2:89–114
   Google Scholar
• Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114: e1–8
   PubMed Web of Science ®Google Scholar
• Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:647–55
   PubMed Web of Science ®Google Scholar
• Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140–7
   PubMed Web of Science ®Google Scholar
• Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatr Res 1991;36:141–55
   PubMed Web of Science ®Google Scholar
• Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997;36:589–96
   PubMed Web of Science ®Google Scholar
• Spilker B. Guide to Clinical Trials. New York, NY: Raven Press, 1991
   Google Scholar
• NHS Centre for Reviews and Dissemination. CRD Report Number 24, Outcomes measurement in psychiatry: a critical review of outcomes measurement in psychiatric research and practice. York, NHS Centre for Reviews and Dissemination, July 2003
   Google Scholar
• Nord E, Pinto JL, Richardson J, et al. Incorporating societal concern for fairness in numerical valuations of health programs. Health Econ 1999:8:25–39
   PubMed Web of Science ®Google Scholar
• Richardson J, McKie J. Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health care sector? Social Sci Med 2005;60:265–75
   PubMed Web of Science ®Google Scholar
• Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisation and people’s preferences: a methodological review of the literature. Health Econ 2005;14:197–208
   PubMed Web of Science ®Google Scholar
• Mortimer D. The value of thinly spread QALYs. Pharmacoeconomics 2006;24:845–53
   PubMed Web of Science ®Google Scholar
• Buxton M, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997, 6:217–27
   PubMed Web of Science ®Google Scholar
• Porzsolt F, Kajnar H, Awa A, et al. Validity of original studies in health technology assessment reports: significance of standardized assessment and reporting. Int J Health Technol Assess Health Care 2005;21:410–13
   PubMed Web of Science ®Google Scholar